GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » PensionAndRetirementBenefit

CERO (CERo Therapeutics Holdings) PensionAndRetirementBenefit : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings PensionAndRetirementBenefit?

CERo Therapeutics Holdings's PensionAndRetirementBenefit for the quarter that ended in Dec. 2024 was $0.00 Mil.


CERo Therapeutics Holdings PensionAndRetirementBenefit Historical Data

The historical data trend for CERo Therapeutics Holdings's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings PensionAndRetirementBenefit Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
PensionAndRetirementBenefit
- - - -

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PensionAndRetirementBenefit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

CERo Therapeutics Holdings PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


CERo Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, South San Francisco, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings Headlines

From GuruFocus